Immunoglobulin Efficacy and Immune Profiling in Antibody Immunodeficiency
NCT07516002 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 15
Last updated 2026-04-07
Summary
This study aims to systematically evaluate the dynamic alterations in peripheral immune subsets among patients with antibody Immunodeficiency undergoing Immunoglobulin therapy
Conditions
- Primary Immunodeficiency Diseases
Sponsors & Collaborators
-
Peking University People's Hospital
lead OTHER
Principal Investigators
-
Zhanguo Li · Study Principal Investigator Peking University Institute of Rheuamotology and Immunology
Eligibility
- Min Age
- 5 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-04-01
- Primary Completion
- 2029-10-01
- Completion
- 2029-12-30
More Related Trials
-
Universal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid Tumors
NCT05976906 ·Status: UNKNOWN ·Phase: PHASE1
-
TIGIT in Patients With Chronic Myeloid Leukemia
NCT04818619 ·Status: UNKNOWN
-
Studies of the Immune Response in Normal Subjects and Patients With Disorders of the Immune System
NCT00001158 ·Status: COMPLETED
-
Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor
NCT02562963 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Prospective Study to Observe Adverse Effects in Patients Receiving Anti-PD1 Immunotherapy
NCT05669638 ·Status: RECRUITING
-
Development of a New Immunotherapy Using Intramuscular Administration of Autologous Total IgG
NCT03695757 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Natural Killer Cells Reconstitution Kinetics Post Haploidentical Transplantation
NCT02978274 ·Status: UNKNOWN
-
The Role of NK Cells to Detect Blood Infection in ALL.
NCT06160115 ·Status: NOT_YET_RECRUITING
-
Personalized Immune Cell Therapy Targeting Neoantigen of Malignant Solid Tumors
NCT05235607 ·Status: UNKNOWN ·Phase: PHASE1
-
Immunotherapy Using Precision T Cells Specific to Personalized Neo-antigen for the Treatment of Advanced Malignant Tumor of Biliary Tract
NCT02632019 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Immune Profiling for Cancer Immunotherapy Response
NCT06116032 ·Status: RECRUITING
-
Safety and Efficacy Study of Donor Natural Killer Cells Given After Haploidentical Hematopoietic Cell Transplantation
NCT01795378 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy
NCT06089967 ·Status: COMPLETED
-
Immunotherapy for Colorectal Cancers Using CEA-Pulsed Dendritic Cells and Subsequent IL-2 Treatment
NCT00154713 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
The Study of Targeted NY-ESO-1 T Cell Receptor (TCR) Genetic Modified Autologous T Cells Treatment of Advanced Solid Tumors
NCT03047811 ·Status: UNKNOWN ·Phase: NA
-
Predictive Markers of Response and Toxicity in Patients With a Haematological Malignancy Treated With Immunotherapy.
NCT05450367 ·Status: COMPLETED
-
Gene Expression Profiling of Malignant Tumor Predict the Therapeutic Response of DC-CIK Immunotherapy
NCT01906632 ·Status: COMPLETED ·Phase: NA
-
PBMC Collection for Production of UCAR T Cells
NCT04963959 ·Status: UNKNOWN ·Phase: NA
-
Immune Repertoire of Ovarian HGSC
NCT03794115 ·Status: UNKNOWN
-
SYSTEMATIC SYMPTOM ASSESSMENT IN CANCER PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS
NCT04929353 ·Status: UNKNOWN ·Phase: NA
-
Immune Cell Therapy for Advanced Solid Tumors
NCT07260058 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation
NCT02779439 ·Status: UNKNOWN ·Phase: PHASE1
-
Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer
NCT00001582 ·Status: COMPLETED
-
Allogeneic γδ T Cell Therapy for the Treatment of Solid Tumors
NCT04765462 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma
NCT03035331 ·Status: COMPLETED ·Phase: PHASE1/PHASE2